Samsung Bioepis NL B.V.
13 products tracked · names used in filings: Samsung Bioepis NL B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Obodence denosumab | Authorised | 2025-02-12 |
| 🇪🇺 | Xbryk denosumab | Authorised | 2025-02-12 |
| 🇪🇺 | Opuviz aflibercept | Authorised | 2024-11-13 |
| 🇪🇺 | Eksunbi ustekinumab | Withdrawn | 2024-09-12 |
| 🇪🇺 | Pyzchiva ustekinumab | Authorised | 2024-04-19 |
| 🇪🇺 | Epysqli eculizumab | Authorised | 2023-05-26 |
| 🇪🇺 | Byooviz ranibizumab | Authorised | 2021-08-18 |
| 🇪🇺 | Onbevzi bevacizumab | Withdrawn | 2021-01-11 |
| 🇪🇺 | Aybintio bevacizumab | Authorised | 2020-08-19 |
| 🇪🇺 | Ontruzant trastuzumab | Authorised | 2017-11-15 |
| 🇪🇺 | Imraldi adalimumab | Authorised | 2017-08-24 |
| 🇪🇺 | Flixabi infliximab | Authorised | 2016-05-26 |
| 🇪🇺 | Benepali etanercept | Authorised | 2016-01-13 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.